MedTrace Logo

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

NCT02067416 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-02-02

No results posted yet for this study

Summary

Study of the assay, Mammostrat®. to verify its utility as a predictor or outcome tool to determine whom would benefit from chemotherapy prior to surgery. Also could be used as a clinical marker to identify patients with breast cancer who do not benefit from some preoperative chemotherapies.

Conditions

Interventions

DRUG

Anthracycline based chemotherapy

standard of care neoadjuvant treatment with anthracycline based chemotherapy

DRUG

taxane-based chemotherapy

neoadjuvant taxane based chemotherapy given as standard of care

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • The Methodist Hospital Research Institute

    collaborator OTHER

  • Jenny C. Chang, MD

    lead OTHER

Principal Investigators

  • Angel A Rodriguez, MD · The Methodist Hospital Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02067416 on ClinicalTrials.gov